2m 2m 2m 2m 2m 2m 2m
- $3.1MMarket Cap
- N/A1-Year Change
- Asset ManagementIndustry
BNB Plus (BNBX)
Key Performance
More- Earnings Score: N/A
- Momentum Score: N/A
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
QXO agreed to acquire TopBuild for approximately $17 billion to expand its building products capabilities. Multiple companies announced strategic reviews including Voya Financial (urged by activist investor), Rayonier Advanced Materials, BNB Plus, Franklin Street Properties, and Investcorp Credit Management BDC. Notable completed transactions include ServiceNow's $7.75 billion acquisition of Armis, Eli Lilly's $7 billion deal for Kelonia Therapeutics, and Pat McGrath Labs exiting Chapter 11 bankruptcy under new ownership.
04/24/2026, 2:27 PM • Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Multiple health care stocks experienced significant price movements during Monday's after-market trading session, with some companies seeing notable gains while others experienced declines.
09/29/2025, 5:06 PM • Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Multiple healthcare stocks experienced significant price movements during Friday's after-market trading session, with some companies seeing notable gains while others experienced declines.
09/26/2025, 5:06 PM • Benzinga
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
BNB Plus Corp. provides digital asset treasury services. The company offers real-time data tracking of treasury performance and market indicators. The company, through its subsidiaries, also develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in the Americas, Europe, Asia, and internationally. The company engages in the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and nucleic acid production solutions for the biopharmaceutical and diagnostics industries, including LineaDNA, LineaRNAP, and LineaIVT, as well as the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. BNB Plus Corp. was formerly known as Applied DNA Sciences, Inc. and changed its name to BNB Plus Corp. in November 2025. The company was founded in 1983 and is based in Stony Brook, New York.
Key Executives
- Judith Murrah
- Clay Shorrock
- Beth Jantzen
- Sanjay Hurry
- Patrick Brian Horsman
Current Ownership Distribution
- Institutions644,511 (49.91%)
- Insiders569,128 (44.07%)
- Other47,495 (3.68%)
- Mutual Funds30,228 (2.34%)